uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
22.59
+0.05 (0.22%)
Oct 9, 2026, 4:00 PM EDT - Market closed
uniQure Revenue
uniQure had revenue of $5.84M in the quarter ending June 30, 2026, with 11.00% growth. This brings the company's revenue in the last twelve months to $18.67M, up 30.24% year-over-year. In the year 2025, uniQure had annual revenue of $16.10M, down -40.64%. That makes uniQure the 34,165th largest company in the world by revenue and 4,496th in the United States.
Revenue (ttm)
$18.67M
Revenue Growth
+30.24%
P/S Ratio
83.92
Revenue / Employee
$84,489
Employees
221
Market Cap
1.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.10M | -11.02M | -40.64% |
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
| Dec 31, 2018 | 11.28M | -1.82M | -13.91% |
| Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
| Dec 31, 2016 | 25.10M | 14.52M | 137.27% |
| Dec 31, 2015 | 10.58M | 4.44M | 72.25% |
| Dec 31, 2014 | 6.14M | 2.09M | 51.74% |
| Dec 31, 2013 | 4.05M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 68.42K | -174.98K | -71.89% |
| Dec 31, 2005 | 243.40K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 717.00M |
| Innoviva | 440.00M |
| Immunocore Holdings | 430.78M |
| Syndax Pharmaceuticals | 252.25M |
| Stoke Therapeutics | 27.59M |
| Maze Therapeutics | 20.00M |
QURE News
- 5 days ago - uniQure downgraded to Equal Weight from Overweight at Barclays - TheFly
- 8 days ago - uniQure price target lowered to $48 from $65 at RBC Capital - TheFly
- 10 days ago - uniQure price target lowered to $31 from $46 at Goldman Sachs - TheFly
- 10 days ago - uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PRNewsWire
- 10 days ago - uniQure weakness creates attractive opportunity, says Wells Fargo - TheFly
- 10 days ago - RBC says uniQure’s four-year HD data mixed, stock reaction ‘overdone’ - TheFly
- 10 days ago - QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law - Business Wire
- 10 days ago - uniQure ‘mixed’ four-year data complicates durability case, says H.C. Wainwright - TheFly